Want to see IN:JAGSNPHARM full AI Analyst Report?
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹301.80
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹15.36B
Enterprise Value₹14.03B
Total Cash (Recent Filing)₹1.06B
Total Debt (Recent Filing)₹81.65M
Price to Earnings (P/E)36.4
Beta1.02
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)6.40
Shares Outstanding65,835,470
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and meaningful equity growth provide durable financial flexibility. Minimal debt reduces interest burden and refinancing risk, enabling sustained funding for field force, product launches, or opportunistic M&A and cushioning operations against sector cyclicality over the next several quarters.
Strong Cash GenerationOperating cash flow materially exceeding net income and strong free cash flow in 2026 indicate high earnings quality and available internal funding. This underpins sustainable investments in sales/marketing and working capital, and supports shareholder returns or strategic reinvestment across the 2-6 month horizon.
Re-accelerating Revenue And Healthy MarginsA sharp re-acceleration in revenue combined with high gross and operating margins signals strong product pricing power and effective commercial execution. These durable margin levels provide a buffer against cost pressures and support sustainable operating profitability if sales momentum persists.
Bears Say
Profitability VolatilityMaterial year-to-year swings in profitability reduce predictability of future earnings and cash flow, complicating budgeting and capital allocation. Persistent volatility can weaken investor confidence and makes it harder to rely on recurring profits to fund growth or payouts over the medium term.
Net Income Fell Despite Revenue GrowthA decline in net income even as revenue surged suggests margin compression, one-off charges, or rising operating costs. If structural, this indicates top-line gains may not consistently translate to profit, limiting durable improvements in free cash flow and returns to shareholders.
Concentrated Domestic Branded RevenueHeavy reliance on domestic branded prescription sales concentrates revenue risk in India and on physician adoption and distributor execution. This exposure raises vulnerability to local regulatory pricing, competitive branded generics, and demand cycles, constraining diversification over the medium term.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹15.36B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Apr 27, 2026. The company reported ₹1.25 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.25.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 65,835,470 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.256%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spans three primary therapeutic domains: women's health, pain management and analgesia, and general medical care. Within general medicine, the company offers solutions for allergy control, immune and cellular protection, gastrointestinal and mental wellness, anti-infectives, and products specifically for dental and ear, nose, and throat (ENT) conditions. For women's healthcare, their offerings include pregnancy support and treatments for issues related to dysfunctional uterine bleeding. Furthermore, Jagsonpal provides medications for pain relief and skeletal and joint health. These pharmaceutical items are supplied in common forms like tablets, capsules, and syrups. The company operates as a subsidiary under Aresko Progressive Private Limited.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―